Actively Recruiting
Metformin in Parkinson Disease
Led by Tanta University · Updated on 2025-11-21
60
Participants Needed
1
Research Sites
97 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
CONDITIONS
Official Title
Metformin in Parkinson Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 50 years or older
- Confirmed diagnosis of Parkinson's disease
- Currently receiving levodopa/carbidopa therapy
You will not qualify if you...
- Secondary causes of parkinsonism
- Taking anti-inflammatory drugs
- Atypical parkinsonian syndromes
- Prior stereotaxic surgery for Parkinson's disease
- Pregnancy and lactation
- Cardiovascular disease
- Coagulation disorders
- Active malignancy
- Addiction to alcohol and/or drugs
- Known allergy to the studied medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University
Tanta, Egypt, 31511
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here